The Elizabeth Holmes Story Revisited: What the Theranos Scandal Teaches About Startup Governance
The myth of a start-up usually tells about a founder who refuses to take an answer like “it cannot be done.” While that determination can prove to be a strong impulse, it can reach a point where confidence starts replacing any actual proof. This is especially dangerous when health is involved. The story of Elizabeth Holmes and Theranos is fascinating for this reason. It is not simply a story of a fallen entrepreneur or unsuccessful medical innovation. It is a matter of governance that failed to ensure that crazy ideas receive the level of scrutiny they deserve.
More than a decade after the company gained public attention, the legal proceedings shed clarity on the repercussions. In 2022, Elizabeth Holmes was pronounced guilty and charged with four counts of fraud regarding the investors. She was sentenced to 135 months in prison and ordered to pay $452 million together with “Sunny” Balwani, the former executive at Theranos.
When the Founder Becomes Bigger Than the Company
In 2003, the idea behind Theranos was based on the notion of blood analysis, which could allow tests to be conducted using a tiny sample, thus making testing easier and more affordable. Theranos’ project was clear for all to comprehend, while Holmes became a symbol of it. Wealthy investors and prominent supporters were eager to get involved in the start-up, grasping that Theranos’ technology had a promising future.
This situation guarantees that the process of governing the company will differ from others. The founder can become the key asset of the company and the key factor of risk as well. Elizabeth Holmes was both CEO and chair at Theranos, while Balwani had major controlling rights. This led to a situation where one person had major power in a very important place.
The gravity of the case simply makes it impossible to view it as a simple misunderstanding. According to the SEC, Theranos raised over $700 million from its investors while providing false or misleading information on the company’s technology, business partners, and financial performance figures. It was reported that the company planned to make over $100 million in sales in 2014, while the real sales hardly exceeded $100,000.
A Famous Board Is Not Necessarily a Strong Board
The most significant governance lesson from Elizabeth Holmes may lie in the boardroom. Theranos gathered an impressive group of former government officials and business figures, including Henry Kissinger, George Shultz, William Perry, James Mattis, and others. The impact of these names constituted an impressive step towards Theranos’ institutional credibility.
However, it should be noted that the story of Elizabeth Holmes is valuable from a broader angle. A tech company requires directors capable of challenging its main technical principles. A new pharmaceutical company needs people familiar with the process of clinical development. A cybersecurity company needs directors who can challenge uncomfortable questions regarding its architecture and vulnerabilities. Financial technologies require directors who can understand both its regulation and growth. In a nutshell, a board cannot provide effective and efficient control if it lacks the language.
Growth Cannot Outrun Verification
The healthcare component makes the Elizabeth Holmes case especially significant. Whereas a software company may be able to survive a defective feature after issuing an upgrade, a lab cannot afford to treat faulty test results like any ordinary flaw in a product. Blood test results can impact various aspects such as diagnosis, treatment, and patients’ comprehension of their health status.
Eventually, regulators discovered multiple issues in Theranos’s lab. In 2016, the Centers for Medicare & Medicaid Services (CMS) uncovered various deficiencies in testing, monitoring, and staffing, resulting in an immediate risk to patients’ health and safety.
The essence of this governance lesson is that regulatory compliance must not be treated as yet another duty while focusing on interesting aspects of business. For companies operating in heavily regulated sectors, compliance becomes an integral part of a business’ output. Thus, any board considering this as something less relevant is ignoring one of the key operational risks.
This is the reason why Elizabeth Holmes should not be seen only as an example of how far ambition and deception can go. The Theranos case demonstrates consequences of a company allowing its story to become much more sophisticated than the underlying evidence.
What Startup Boards Should Remember
The lasting importance of Elizabeth Holmes’ tale is rooted in the questions she leaves behind for entrepreneurs, investors and board members of today. Does the board possess the essential expertise to challenge the goods and services? Is it feasible for board members to meet absent management? Are professionals independent enough to investigate vital information? Is there a system of rewarding those individuals who come up with unpleasant truths within companies? Are major partnerships verified independently?
None of these approaches guarantees the success of the startup. The purpose of their existence is more basic. Instead of assurance, these approaches are supposed to ensure that the uncertainty cannot be masqueraded as certainty.
The Elizabeth Holmes story gives a warning that has to do with reputation. Famous members of the board can pave the way for confidence but cannot serve as evidence. Investors can bring financial resources, clients – and media can accelerate the process but don’t relieve the company of the necessity to do the validating job itself.
The most important thing to take away from Theranos and Elizabeth Holmes is to not be wary of daring entrepreneurs. It is to create businesses where audacious concepts must withstand critical scrutiny. Charisma may draw in investors, ambition can launch a company, and vision can motivate staff. However, proof must have the last say when a product claims to improve people’s lives.
